Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Johnson & Johnson single-shot COVID-19 vaccine demonstrated a durable immune response and elicited dual mechanisms of protection against delta and other SARS-CoV-2 variants in data published in NEJM

Written by | 30 Jul 2021

Interim results from a Phase 1/IIa sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by… read more.

Lilly and Incyte provide update on supplemental NDA for baricitinib for the treatment of moderate to severe atopic dermatitis

Written by | 24 Jul 2021

Eli Lilly and Company and Incyte announced that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application… read more.

Ivermectin – the unfolding story

Written by | 24 Jul 2021

IMI has been reporting on ivermectin since December 2020, keeping our readers and viewers up-to-date with research and practice developments. To mark World Ivermectin Day (24th July 2021),… read more.

Hospitals prevent deadly fungal infection during pandemic

Written by | 20 Jul 2021

As COVID-19 infections threatened to overwhelm hospitals in March 2020, infection control specialists worried not just about SARS-CoV-2 but also about other viral, bacterial and fungal diseases. C…. read more.

EMA boost for COVID-19 vaccine production

Written by | 19 Jul 2021

The European Medicines Agency has approved additional manufacturing capacity for two companies producing vaccines against COVID-19. The news comes as European countries continue to roll out vaccines amid… read more.

Immunologists discover ‘spider web’ mechanism that traps viruses

Written by | 19 Jul 2021

Scientists at McMaster University in Toronto have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the… read more.

Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response

Written by | 18 Jul 2021

Johnson & Johnson announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants…. read more.

SARS-CoV-2 infection starts in nasal ciliated cells

Written by | 10 Jul 2021

Journal of Clinical Investigation The discovery that multiciliated cells in the nasal epithelium are the first cells to be targeted in early COVID-19 infection might provide the rationale… read more.

Employed individuals more likely to contract the flu, study shows

Written by | 5 Jul 2021

A University of Arkansas researcher and international colleagues found that employed individuals, on average, are 35.3% more likely to be infected with the flu virus. The findings confirm… read more.

Antidepressant prescribing during covid-19

Written by | 2 Jul 2021

Interview and article by Christine Clark. Some four million extra prescriptions for antidepressants were issued in 2020 compared to 2019 but the cost to the NHS increased by… read more.

TGA Australia approves COVID-19 vaccine Janssen to prevent COVID-19 – Janssen Cilag Pty. Ltd.

Written by | 29 Jun 2021

On 25 June 2021 the Therapeutic Goods Administration (TGA) granted provisional approval to Janssen-Cilag Pty Ltd (known as Johnson & Johnson overseas) for its COVID-19 vaccine Janssen, making… read more.

Gilead’s Veklury is associated with a reduction in mortality rate in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets

Written by | 26 Jun 2021

Gilead Sciences, Inc. announced positive data from three retrospective studies of the real-world treatment of patients hospitalized with COVID-19, adding to the body of mortality and hospital discharge… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.